TScan Therapeutics Enters Material Agreement
Ticker: TCRX · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $7.1300, $7.1299, $144.7 million, $165.9 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-condition
TL;DR
TScan Therapeutics signed a big deal on 4/16, more details to come.
AI Summary
TScan Therapeutics, Inc. announced on April 16, 2024, that it entered into a Material Definitive Agreement. The company also reported on its Results of Operations and Financial Condition. Specific details regarding the agreement and financial results were not provided in this initial filing.
Why It Matters
This filing indicates a significant business development for TScan Therapeutics, potentially impacting its future operations and financial standing.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that may affect the company's financial performance and stock price.
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Registrant
- April 16, 2024 (date) — Date of earliest event reported
- 880 Winter Street (address) — Business and Mail Address
- Waltham (city) — Business and Mail City
- Massachusetts (state) — Business and Mail State
- 02451 (zip_code) — Business and Mail Zip
- (857) 399-9500 (phone_number) — Business Phone
FAQ
What is the nature of the Material Definitive Agreement entered into by TScan Therapeutics?
The filing states that TScan Therapeutics, Inc. entered into a Material Definitive Agreement on April 16, 2024, but does not provide specific details about the agreement itself.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 16, 2024.
What is TScan Therapeutics, Inc.'s principal executive office address?
TScan Therapeutics, Inc.'s principal executive offices are located at 880 Winter Street, Waltham, Massachusetts 02451.
What is the company's telephone number?
The company's telephone number, including area code, is (857) 399-9500.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhibits.
Filing Stats: 1,439 words · 6 min read · ~5 pages · Grade level 11.6 · Accepted 2024-04-17 06:25:33
Key Financial Figures
- $0.0001 — which registered Voting Common Stock, $0.0001 par value per share TCRX The Nasdaq
- $7.1300 — on Stock"), at a price to the public of $7.1300 per share, and (b) pre-funded warrants
- $7.1299 — Warrants"), at a price to the public of $7.1299 per warrant with an exercise price of $
- $144.7 million — ffering expenses, will be approximately $144.7 million (or approximately $165.9 million if the
- $165.9 million — mately $144.7 million (or approximately $165.9 million if the underwriters exercise their over
- $162.8 million — quivalents and marketable securities of $162.8 million. This preliminary financial information
Filing Documents
- d816959d8k.htm (8-K) — 36KB
- d816959dex11.htm (EX-1.1) — 218KB
- d816959dex41.htm (EX-4.1) — 67KB
- d816959dex51.htm (EX-5.1) — 8KB
- d816959dex991.htm (EX-99.1) — 9KB
- d816959dex992.htm (EX-99.2) — 10KB
- g816959dsp12.jpg (GRAPHIC) — 14KB
- g816959dsp17.jpg (GRAPHIC) — 8KB
- g816959dsp17a.jpg (GRAPHIC) — 8KB
- g816959g0417112720660.jpg (GRAPHIC) — 4KB
- 0001193125-24-098509.txt ( ) — 600KB
- tcrx-20240416.xsd (EX-101.SCH) — 3KB
- tcrx-20240416_lab.xml (EX-101.LAB) — 18KB
- tcrx-20240416_pre.xml (EX-101.PRE) — 11KB
- d816959d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement dated April 16, 2024. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (contained in Exhibit 5.1). 99.1 Launch Press Release dated April 16, 2024. 99.2 Pricing Press Release dated April 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are based on the Company's beliefs and assumptions and on information currently available to the Company on the date of this Current Report. These forward-looking statements involve substantial risks and uncertainties. Any statements in this Current Report on Form 8-K other than statements of historical fact, including statements about the Company's future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company's strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company's views only as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law even if new information becomes available in the future. SIGNATURE Pursuant to the requirements of the Securit